

CORRESPONDENCE

Open Access



Further observation of Hemoglobin Fontainebleau (α21(B2) Ala-Pro) in a Turkish family

Nejat Akar¹, Serdar Ceylaner², Yasemin Ardicoglu Akisin^{3*}  and Gokce Su Tastan⁴

To the Editor,

Several hemoglobin (Hb) variants have been reported in Turkish population [1–3]. Herein, we represent a nucleotide alteration of the alpha-2 chain variant, Hemoglobin Fontainebleau (α21(B2) Ala-Pro) in an 8-year-old male Turkish child living in Ankara, Turkey. He was admitted to the Hospital Pediatrics Department for routine check-up. His physical examination was normal, and there was no positive consanguinity between his parents. High red blood cell count and low mean corpuscular volume were detected in complete blood count (CBC) (Fig. 1a). High-performance liquid chromatography (HPLC) showed an asymmetry (shoulder formation) in the descending part of A0 and in the A2 curve. Levels of HbA, HbA2, and HbF were observed as 93.25%, 3.55%, and 1.07%, respectively (Fig. 1a). His mother and 6-year-old sister were also screened. Their HPLC chromatograms showed similar pattern (Fig. 1b, c).

Sequence analysis of HBA1 and HBA2 genes were performed by using MiSeq next-generation sequencing (NGS) platform (Illumina, San Diego, CA, USA). Genomic DNA was extracted by using the QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany). All coding regions and exon-intron boundaries of the genes were amplified using PCR primers, designed with PRIMER®-Primer Designer v.2.0 (Scientific & Educational Software programme) software. Alignment was done by using

hg19 genome with MiSeq Reporter software (Illumina Inc.), and analysis was done with IGV 2.3 (Broad Institute) software. These genes were also tested for common deletions with MLPA (multiplex ligation-dependent probe amplification) method (SALSA MLPA P140 HBA probemix, MRC Holland, Amsterdam, Holland). NM_000558.5(HBA1):c.64G>C (p.Ala22Pro) was detected by sequence analysis while MLPA test was normal (Fig. 1a, b).

Written informed consent for genetic analysis was obtained both from the child's parents and from the mother.

Hemoglobin Fontainebleau (α21(B2) Ala-Pro) is a rarely reported hemoglobin variant. It was first reported in an Italian family without DNA analysis in 1989 and later on in India, Canada, South Cyprus, United Arab Emirates, Iraq (family living in New Zealand), and Turkey. It was described as a silent mutation and was also reported in combination with heterozygote forms of sickle cell, hereditary spherocytosis, and Hb Punjab [1, 4–6].

It is interesting that the cases identified were on historical migration routes. Since Turkey is located at the intersection of two continents, it is not surprising that many different hemoglobin variants are observed. Further observation of Hb Fontainebleau (α21(B2) Ala-Pro) suggests that this variant is found sporadically in the Turkish population.

* Correspondence: yardicoglu@gmail.com

³Department of Biochemistry, Faculty of Medicine, TOBB Economy and Technology University, Yasam Cad. No5 Sogutozu, 06510 Ankara, Turkey
Full list of author information is available at the end of the article




Fig. 1 CBC, HPLC chromatograms, and HBA2 gene. The figure includes the HPLC histograms and HBA2 gene sequence analysis below the complete blood count and ferritin levels of the patient (**a**), his mother (**b**), and sister (**c**). The asymmetry (shoulder formation) in the descending part of A0 and in the A2 curve was indicated with an arrow on the chromatogram

Abbreviations

CBC: Complete blood count; Hb: Hemoglobin; HPLC: High-performance liquid chromatography; MLPA: Multiplex ligation-dependent probe amplification; NGS: Next-generation sequencing

Acknowledgements

Not applicable.

Authors' contributions

NA contributed to the clinical diagnosis and reviewing of the manuscript. SC contributed to the sequence analysis. YAA contributed to the drafting and reviewing of the manuscript. GST contributed to the drafting of the manuscript. All authors have read and approved the final manuscript.

Funding

No funding was received.

Availability of data and materials

The authors can confirm that all relevant data are included in the manuscript.

Ethics approval and consent to participate

Each author has participated sufficiently in the work to take public responsibility for the content, and also, the authors had no conflict of interest to declare in relation to this manuscript. As it was a retrospective study, ethics approval was not taken.

Consent for publication

Written informed consent for genetic analysis and publication was obtained from the patient's family.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Pediatrics, Faculty of Medicine, TOBB Economy and Technology University, Ankara, Turkey. ²Intergen Genetic Centre, Ankara, Turkey. ³Department of Biochemistry, Faculty of Medicine, TOBB Economy and Technology University, Yasam Cad. No5 Sogutozu, 06510 Ankara, Turkey. ⁴Gokce Su TASTAN, TOBB Economy and Technology University, Faculty of Medicine, 5th year Student, Ankara, Turkey.

Received: 5 October 2019 Accepted: 9 January 2020

Published online: 20 January 2020

References

- Altay C (2002) Abnormal hemoglobins in Turkey. *Turk J Haematol* 19:63–74
- Akar E, Akar N (2007) A review of abnormal hemoglobins in Turkey. *Turk J Hematol* 24:143–145
- Akar N (2014) An updated review of abnormal hemoglobins in the Turkish population. *Turk J Haematol* 31(1):97–98
- Wajcman H, Blouquit Y, Gombaudo-Daintonge G, Riou J, Galacteros F (1989) Hb Fontainebleau alpha 21(B2)Ala-Pro, a new silent mutant hemoglobin. *Hemoglobin* 13:421
- Upadhye DS, Jain D, Nair SB, Nadkarni AH, Ghosh K, Colah RB (2012) First case of Hb Fontainebleau with sickle haemoglobin and other non-deletional α gene variants identified in neonates during newborn screening for sickle cell disorders. *J Clin Pathol* 65:654–659
- Rodríguez-Capote K, Estey MP, Barakauskas V, Bordeleau P, Christensen CL, Zuberbuhler P, Higgins TN (2015) A novel double heterozygous Hb Fontainebleau/HbD Punjab hemoglobinopathy. *Clin Biochem* 48(13–14):904–907

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.